Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

AbbVie releases preliminary results from ABT-414 Phase I study in patients with recurrent or unresectable GBM

AbbVie released preliminary results from an ongoing Phase I study with ABT-414, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody drug conjugate, in combination with temozolomide, which showed four objective responses, including one complete response, in patients with recurrent or unresectable glioblastoma multiforme.

31 May 2014

Women with metastatic breast cancer can receive bisphosphonates less frequently and safely

Women with metastatic breast cancer to the bone may be able to receive bisphosphonates, the bone-targeting class of drugs like zoledronic acid, less often after the first year of monthly administration.

31 May 2014

Patrys reports positive results from PAT-SM6 clinical trial in patients with multiple myeloma

Patrys Limited, a clinical stage biotechnology company, is pleased to announce the clinical results from a patient treated with PAT-SM6 in combination with other marketed multiple myeloma drugs.

28 May 2014

Alligator Bioscience acquires rights to drug development candidate ADC-1013

BioInvent International AB (publ) (OMXS:BINV) today announced that the company has sold back all its rights to drug development candidate ADC-1013 to former partner Alligator Bioscience for an undisclosed sum.

27 May 2014

Elotuzumab granted Breakthrough Therapy Designation for treatment of multiple myeloma

Bristol-Myers Squibb Company and AbbVie today announced that the U.S. Food and Drug Administration (FDA) has granted elotuzumab, an investigational humanized monoclonal antibody, Breakthrough Therapy Designation for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in patients who have received one or more prior therapies.

20 May 2014

EntreMed reports net loss of $1.5M in first quarter 2014

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, today reported financial results for the three months ended March 31, 2014.

15 May 2014

New study presents novel strategy for treating multiple myeloma

A new study by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) provides evidence that genetically modifying immune cells might effectively treat multiple myeloma, a disease that remains incurable and will account for an estimated 24,000 new cases and 11,100 deaths in 2014

13 May 2014

The Leukemia & Lymphoma Society passes $1 billion mark in blood cancer research investment

The Leukemia & Lymphoma Society announced that it has passed the $1 billion mark in research investment, a significant milestone in the cancer research landscape as LLS continues its 65 year pursuit of advancing breakthrough therapies, finding cures and ensuring access to life-saving therapies for all blood cancer patients.

8 May 2014

Janssen expands collaboration with IPM for development of dapivirine to prevent HIV

Janssen R&D Ireland Ltd. (Janssen) today announced that it has expanded its collaboration with the International Partnership for Microbicides (IPM) for the development and delivery of dapivirine (TMC120) for the prevention of HIV.

8 May 2014

Ligand's total revenues increase 37% to $16.0 million in first quarter 2014

Ligand Pharmaceuticals Incorporated today reported financial results for the three months ended March 31, 2014, and provided an operating forecast and program updates.

7 May 2014

NCCN publishes new patient resource for stage 0 breast cancer

The National Comprehensive Cancer Network (NCCN), with the support of the NCCN Foundation®, announces the availability of the NCCN Guidelines for Patients: Breast Cancer Stages 0 - IV—the latest addition to the library of NCCN Guidelines for Patients available online free-of-charge at NCCN.org/patients.

6 May 2014

Virginia researchers develop new combination therapy that could potentially treat multiple myeloma

Each year, more than 25,000 Americans are diagnosed with multiple myeloma, a form of blood cancer that often develops resistance to therapies.

2 May 2014

Captisol-enabled Melphalan meets primary end points in phase 2 pivotal trial

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that its pivotal trial of Captisol-enabled (propylene glycol-free) Melphalan met its primary end points.

23 Apr 2014

Skin docs prescribe costlier drugs after free samples

In other news, panels recommend a costly hepatitis C drug for the sickest patients, and cancer doctors will compare the value of costly cancer drugs.

18 Apr 2014

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Johnson & Johnson today announced sales of $18.1 billion for the first quarter of 2014, an increase of 3.5% as compared to the first quarter of 2013. Operational results increased 5.3% and the negative impact of currency was 1.8%. Domestic sales increased 2.2%. International sales increased 4.5%, reflecting operational growth of 7.9% and a negative currency impact of 3.4%.

15 Apr 2014

Drugs used to treat osteoporosis appear to prevent cell membrane repair

A class of drugs widely used to treat osteoporosis appears to impede a cell's ability to repair a protective outer membrane that helps determine what enters and exits, researchers report.

15 Apr 2014

BioLineRx to initiate Phase 1/2 clinical trial on new drug candidate for CML treatment

BioLineRx, a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that Prof. Arnon Nagler, Director of the Hematology Division and Bone Marrow Transplantation Center at Sheba Medical Center, Israel, has received final regulatory approval to evaluate BioLineRx's BL-8040 as a treatment for chronic myeloid leukemia (CML) in a Phase 1/2 clinical study.

10 Apr 2014

$Patrys reports final results from PAT-SM6 Phase I/IIa study in patients with refractory or relapsed MM$

Patrys reports final results from PAT-SM6 Phase I/IIa study in patients with refractory or relapsed MM

Patrys Limited, a clinical stage biotechnology company, is pleased to announce the final results from its Phase I/IIa, open-label study in patients with refractory or relapsed multiple myeloma (MM).

28 Mar 2014

Adaptimmune awarded £2.1 million grant to expedite development of engineered T cell therapy

Adaptimmune today announced that it has been awarded a grant of £2.1 million from the Biomedical Catalyst Fund, managed by the UK’s innovation agency the Technology Strategy Board and the Medical Research Council. The prestigious award will expedite the development of Adaptimmune’s second engineered T cell therapy programme into the clinic in triple negative breast cancer.

26 Mar 2014

CytRx initiates Phase 3 clinical trial to evaluate efficacy of aldoxorubicin in STS patients

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has initiated a pivotal global Phase 3 clinical trial to evaluate the efficacy and safety of aldoxorubicin as a second-line treatment for patients with soft tissue sarcoma (STS) under a Special Protocol Assessment with the FDA.

25 Mar 2014

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

AbbVie releases preliminary results from ABT-414 Phase I study in patients with recurrent or unresectable GBM

Women with metastatic breast cancer can receive bisphosphonates less frequently and safely

Patrys reports positive results from PAT-SM6 clinical trial in patients with multiple myeloma

Alligator Bioscience acquires rights to drug development candidate ADC-1013

Elotuzumab granted Breakthrough Therapy Designation for treatment of multiple myeloma

EntreMed reports net loss of $1.5M in first quarter 2014

New study presents novel strategy for treating multiple myeloma

The Leukemia & Lymphoma Society passes $1 billion mark in blood cancer research investment

Janssen expands collaboration with IPM for development of dapivirine to prevent HIV

Ligand's total revenues increase 37% to $16.0 million in first quarter 2014

NCCN publishes new patient resource for stage 0 breast cancer

Virginia researchers develop new combination therapy that could potentially treat multiple myeloma

Captisol-enabled Melphalan meets primary end points in phase 2 pivotal trial

Skin docs prescribe costlier drugs after free samples

Johnson & Johnson's sales increase 3.5% to $18.1 billion in first quarter 2014

Drugs used to treat osteoporosis appear to prevent cell membrane repair

BioLineRx to initiate Phase 1/2 clinical trial on new drug candidate for CML treatment

Patrys reports final results from PAT-SM6 Phase I/IIa study in patients with refractory or relapsed MM

Adaptimmune awarded £2.1 million grant to expedite development of engineered T cell therapy

CytRx initiates Phase 3 clinical trial to evaluate efficacy of aldoxorubicin in STS patients

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in